中国医药教育协会妇科肿瘤专业委员会委员
Member of the Gynecologic Oncology Committee of China Medical Education Association
中国优生科学协会肿瘤生殖学分会委员
Member of the Tumor Reproductive Branch of the ChinaHealthy Birth Science Association
上海市医学会妇产科分会青年委员
Youth Committee Member of Obstetrics and Gynecology Branch of Shanghai Medical Association
上海市医师协会微无创医学专业委员会委员
Member of the Minimally Invasive Surgery Medicine Professional Committee of the Shanghai Medical Association
上海市社会医疗机构协会第二届妇产科分会委员
Member of the 2nd Shanghal Association of social medical Ititutions branch of Obstetrics and Gynecology
上海市虹口区妇科质控组长
Head of Gynecological Quality Control Team in Hongkou District, Shanghai
上海市虹口区工匠
Craftsmen from Hongkou District, Shanghai
同济大学附属上海市第四人民医院妇产科执行主任、支部书记双带头人，首届上海市“优秀青年医师”成员，法国里昂市立医院访问学者，主要致力于妇科良恶性肿瘤及不孕症生殖相关的临床诊治，倡导微创及医工结合创新治疗理念，擅长应用单孔、多孔腹腔镜手术技术治疗妇科良恶性疾病，同时钻研新生物材料在妇科疾病治疗的基础与临床研究。主持多项课题研究，近三年来主持包括国家自然科学基金（面上项目）、虹口区科委、区卫健委课题三项，多年来在国内外期刊发表论文24余篇，其中SCI收录21篇，最高影响因子18.5，获批国家发明专利2项。
以下是重点代表性成果：
（一）通过设计生物相容性超声响应水凝胶负载TGF-β模拟肽，实现稳定储存与超声触发释放；激活TGF-β/SMAD通路，促进内膜上皮/间质细胞增殖、迁移及分化，利用水凝胶三维网络增强细胞功能；该成果创新性非侵入性超声响应+模拟肽递送策略，解决传统治疗靶向性差、药物不可控的痛点，为跨学科精准解决生殖修复难题提供研究框架和转化基础。(ACS Appl.Mater.Interfaces.2024）
（二）明确了circRNA（hsa_circ_0013561）在卵巢癌中的作用及机制，证实其在卵巢癌细胞组织中高表达，且与肿瘤转移、预后不良显著相关，并通过实验证实促癌功能。该成果为卵巢癌发病机制提供新视角，为分子靶向、基因治疗研发奠定基础，改善患者生存。(Cancer Gene Ther.2024)
（三）设计并构筑了纳米多孔等离子体金针阵列，进而实现高效胞内递送代谢调控蛋白。不同于传统细胞毒药物选择性差、毒副作用强、易产生耐药性等特点，蛋白类药物具有高选择性、低毒性的优点。这项基础工作为生物大分子的细胞内传递提供了一种方便的途径，也为克服癌症耐药性提供了一种可能的解决方案。(Small.2025)
I am currently the Executive Director of the Department of Obstetrics and Gynecology and the "Dual Leader" of the Party Branch at Shanghai Fourth People's Hospital Affiliated to Tongji University, a member of the first batch of Shanghai "Outstanding Young Physicians", and a visiting scholar at Hôpital Municipal de Lyon in France. I am mainly committed to the clinical diagnosis and treatment of benign and malignant gynecological tumors, as well as infertility and reproductive-related disorders. I advocate the innovative treatment concepts of minimally invasive techniques and the integration of medicine and engineering, and am proficient in applying single-port and multi-port laparoscopic surgical techniques for the management of benign and malignant gynecological diseases. Meanwhile, I dedicate myself to basic and clinical research on the application of novel biomaterials in the treatment of gynecological conditions. I have presided over multiple research projects, including three projects in the past three years: a General Program of the National Natural Science Foundation of China, and projects funded by the Hongkou District Science and Technology Commission and the Hongkou District Health Commission. Over the years, I have published more than 24 papers in domestic and foreign journals, 21 of which are indexed in SCI (Science Citation Index), with the highest impact factor of 18.5, and have obtained 2 national invention patents.
The following are the key representative achievements：
(1) By designing a biocompatible ultrasound-responsive hydrogel loaded with TGF-β mimetic peptides, I have achieved stable storage and ultrasound-triggered controlled release of the peptides. This system activates the TGF-β/SMAD signaling pathway, promotes the proliferation, migration, and differentiation of endometrial epithelial and stromal cells, and enhances cellular functions through the hydrogel’s three-dimensional network. This achievement, featuring an innovative non-invasive ultrasound-responsive + mimetic peptide delivery strategy, addresses the limitations of poor targeting and uncontrollable drug release in traditional treatments, and provides a research framework and translational basis for interdisciplinary precision solutions to reproductive tissue repair challenges. (ACS Appl. Mater. Interfaces. 2024)
(2) I have clarified the role and mechanism of circRNA (hsa_circ_0013561) in ovarian cancer, confirmed its overexpression in ovarian cancer tissues and cells, and its significant correlation with tumor metastasis and poor prognosis, and verified its oncogenic function through in vitro and in vivo experiments. This achievement provides a new insight into the pathogenesis of ovarian cancer, lays a foundation for the research and development of molecular targeted therapy and gene therapy, and contributes to improving patient survival outcomes. (Cancer Gene Ther. 2024)
(3) I have designed and constructed a nanoporous plasmonic gold needle array, thereby enabling efficient intracellular delivery of metabolic regulatory proteins. Unlike traditional cytotoxic chemotherapeutic agents, which have poor selectivity, strong adverse effects, and are prone to inducing drug resistance, protein-based therapeutics offer advantages of high selectivity and low toxicity. This basic research work provides a facile approach for the intracellular delivery of biomacromolecules and a potential strategy for overcoming cancer drug resistance. (Small. 2025)
